ABBV supply chain intelligence for AbbVie Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
AbbVie Inc. (ABBV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals, Inc. | 92% | Reciprocal relationship from IRWD graph: The Company records royalties on sales of CONSTELLA in Canada and LINZESS in Mexico in the period earned. |
| XLO | Xilio Therapeutics, Inc. | 92% | Reciprocal relationship from XLO graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from XLO graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from XLO grap… |
| ALDX | Aldeyra Therapeutics, Inc. | 90% | Reciprocal relationship from ALDX graph: Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap. |
| IMNM | Immunome, Inc. | 85% | Reciprocal relationship from IMNM graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IMNM graph: generated any revenue from product sales and do not expect to do so for the … |
| CTMX | CytomX Therapeutics, Inc. | 80% | Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from JNJ grap… |
| ESGL | ESGL Holdings Limited | 62% | Reciprocal relationship from ESGL graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from ESGL graph: ), STMicroelectronics Pte Ltd (“STMicro”) and Systems on Silicon Manufacturi… |
| IRON | Disc Medicine, Inc. | 62% | Reciprocal relationship from IRON graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON g… |
| LCTX | Lineage Cell Therapeutics, Inc. | 62% | Reciprocal relationship from LCTX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from LCTX g… |
| NBP | NovaBridge Biosciences | 62% | Reciprocal relationship from NBP graph: roduction, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the abse… |
| PHVS | Pharvaris N.V. | 62% | Reciprocal relationship from PHVS graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from PHVS g… |
| RGNX | REGENXBIO Inc. | 62% | Reciprocal relationship from RGNX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from RGNX g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IRON | Disc Medicine, Inc. | 92% | Reciprocal relationship from IRON graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON graph: Under the AbbVie Agreement, we obtained an exclusive, worldwide license, wit… |
| U-S-WHOLESALERS | U-S-WHOLESALERS | 92% | three U.S. wholesalers accounted for 78 % as of March 31, 2026 and 84 % as of December 31, 2025, and substantially all of AbbVie’s pharmaceutical product net revenues in the United States were to the… |
| SION | Sionna Therapeutics, Inc. | 90% | Reciprocal relationship from SION graph: We have entered into license agreements with Sanofi and AbbVie, pursuant to which, among other things, we have secured exclusive licenses for certain intellec… |
| JANSSEN-BIOTECH-INC | JANSSEN-BIOTECH-INC | 85% | ended March 31, 2026 and $ 242 million for the three months ended March 31, 2025. Sales and marketing and development costs for the three months ended March 31, 2026 and 2025 were insignificant. Coll… |
| JNJ | Johnson & Johnson | 85% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: ended March 31, 2026 and $ 242 millio… |
| ROCHE-GROUP | ROCHE-GROUP | 85% | rs. The upfront payment of $ 650 million was recorded in acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2026. AbbVie could make addi… |
| ARGX | argenx SE | 80% | Reciprocal relationship from ARGX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from ARGX graph: We currently have collaborative research relationships with various pharmace… |
| CTMX | CytomX Therapeutics, Inc. | 80% | Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement, and from time to time some of our research programs have bee… |
| JNJ | Johnson & Johnson | 72% | ended March 31, 2026 and $ 242 million for the three months ended March 31, 2025. Sales and marketing and development costs for the three months ended March 31, 2026 and 2025 were insignificant. Coll… |
| EXECUTIVE-OVERVIEW-COMPANY | EXECUTIVE-OVERVIEW-COMPANY | 62% | ying notes appearing in Item 1, “Financial Statements and Supplementary Data.” EXECUTIVE OVERVIEW Company Overview AbbVie is a global, diversified research-based biopharmaceutical company positioned … |
| NIMBLE-THERAPEUTICS-INC | NIMBLE-THERAPEUTICS-INC | 62% | s 4 4 Weighted-average diluted shares outstanding 1,774 1,772 Diluted earnings per share attributable to AbbVie Inc. $ 0.39 $ 0.72 Certain shares issuable under stock-based compensation plans were ex… |
| REMEGEN-CO-LTD | REMEGEN-CO-LTD | 62% | s 4 4 Weighted-average diluted shares outstanding 1,774 1,772 Diluted earnings per share attributable to AbbVie Inc. $ 0.39 $ 0.72 Certain shares issuable under stock-based compensation plans were ex… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ABBV-DEBT-39463 | Debt | 90% | debt detail from 424B5 2026-02-26. |
| ABBV-DEBT | Debt stack $64.5B | 90% | Market cache reports total debt of $64.5B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ABBV-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 81,217,516; value $17.66T; as of 2026-03-31. |
| ABBV-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC | VANGUARD PORTFOLIO MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 49,523,078; value $10.77T; as of 2026-03-31. |
| ABBV-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 95% | 13F/ownership overlay lists BARCLAYS PLC; shares held 57,449,643; value $10.63T; as of 2026-03-31. |
| ABBV-OWNER-CAPITAL-RESEARCH-GLOBAL-INVESTORS | Capital Research Global Investors | 95% | 13F/ownership overlay lists Capital Research Global Investors; shares held 31,254,786; value $6.80T; as of 2026-03-31. |
| ABBV-OWNER-JPMORGAN-CHASE-CO | JPMORGAN CHASE & CO | 95% | 13F/ownership overlay lists JPMORGAN CHASE & CO; shares held 56,741,691; value $12.09T; as of 2026-03-31. |
| ABBV-OWNER-DZ-BANK-AG-DEUTSCHE-ZENTRAL-GENOSSENSCHA | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 95% | 13F/ownership overlay lists DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main; shares held 108,874,806; value $15.50T; as of 2026-03-31. |
| ABBV-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 229,760,648; ownership 13.00%; value $49.97T; as of 2026-03-31. |
| ABBV-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 150,749,625; value $32.79T; as of 2026-03-31. |
| ABBV-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 119,713,498; value $27.06T; as of 2026-03-31. |
| ABBV-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | GEODE CAPITAL MANAGEMENT, LLC | 95% | 13F/ownership overlay lists GEODE CAPITAL MANAGEMENT, LLC; shares held 46,737,581; value $10.14T; as of 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | beneficial ownership event from 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | Crum Demetris D | EVP, CHIEF HR OFFICER | sell | 1594 shares |
| ABBV | AbbVie Inc. | 82% | Thakkar Roopal | EVP, R&D and CSO | sell | 8037 shares |
| ABBV | AbbVie Inc. | 82% | Siatis Perry C | EVP, GC AND SECRETARY | option_exercise | 7292 shares |
| ABBV | AbbVie Inc. | 82% | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | sell | 83171 shares |
| ABBV | AbbVie Inc. | 82% | Quaggin Susan E | Director | option_exercise | 71 shares |
| ABBV | AbbVie Inc. | 82% | Saleki-Gerhardt Azita | EVP, CHIEF OPERATIONS OFFICER | sell | 16309 shares |
| ABBV | AbbVie Inc. | 82% | Alpern Robert J | Director | option_exercise | 35 shares |
| ABBV | AbbVie Inc. | 82% | Rapp Edward J | Director | option_exercise | 155 shares |
| ABBV | AbbVie Inc. | 82% | beneficial ownership event from 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | beneficial ownership event from 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | Siatis Perry C | EVP, GC AND SECRETARY | option_exercise | 7292 shares |
| ABBV | AbbVie Inc. | 82% | Quaggin Susan E | Director | option_exercise | 71 shares |
| ABBV | AbbVie Inc. | 82% | Alpern Robert J | Director | option_exercise | 35 shares |
| ABBV | AbbVie Inc. | 82% | Rapp Edward J | Director | option_exercise | 155 shares |
| ABBV | AbbVie Inc. | 82% | beneficial ownership event from 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | beneficial ownership event from 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | beneficial ownership event from 2026-03-31. |
| ABBV | AbbVie Inc. | 82% | Crum Demetris D | EVP, CHIEF HR OFFICER | sell | 1594 shares |
| ABBV | AbbVie Inc. | 82% | Siatis Perry C | EVP, GC AND SECRETARY | sell | 10291 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| PHVS | Pharvaris N.V. | 100.00 | 1 | ['supplier'] |
| IRON | Disc Medicine, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SION | Sionna Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| LCTX | Lineage Cell Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| ABBVIE | ABBVIE | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 1 | ['supplier'] |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ESGL | ESGL Holdings Limited | 100.00 | 1 | ['supplier'] |
| IRWD | Ironwood Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer', 'supplier'] |
| XLO | Xilio Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| AMGEN | AMGEN | 100.00 | 2 | |
| ARGX | argenx SE | 100.00 | 1 | ['customer'] |
| ALDX | Aldeyra Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| AGMB | AgomAb Therapeutics NV | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| FCX | Freeport-McMoRan Inc. | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 |